21 – 30 of 81
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2015
-
Mark
NT-rådets ställningstagande till eculizumab är oacceptabelt
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Slutreplik, Diana Karpman och medförfattare : - NT-rådet bör omedelbart återkalla sitt beslut om eculizumab
(
- Contribution to journal › Debate/Note/Editorial
- 2014
-
Mark
Long-Term Follow-Up of Cyclophosphamide Compared with Azathioprine for Initial Maintenance Therapy in ANCA-Associated Vasculitis.
(
- Contribution to journal › Article
-
Mark
Comparison of phenotype and outcome in microscopic polyangiitis between europe and Japan.
(
- Contribution to journal › Article
- 2013
-
Mark
Long-term follow-up of patients with severe ANCA-associated vasculitis comparing plasma exchange to intravenous methylprednisolone treatment is unclear
(
- Contribution to journal › Article
-
Mark
Revisiting the classification of clinical phenotypes of anti-neutrophil cytoplasmic antibody-associated vasculitis: a cluster analysis
(
- Contribution to journal › Article
-
Mark
Methotrexate remains a valuable option for remission induction of nonsevere antineutrophil cytoplasmic antibody-associated vasculitis: comment on the article by Faurschou et al Reply
(
- Contribution to journal › Letter
- 2012
-
Mark
Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long-term follow-up
(
- Contribution to journal › Article
-
Mark
How can we predict the risk of relapse in antineutrophil cytoplasmic antibody-associated vasculitis? Comment on the article by Walsh et al Reply
(
- Contribution to journal › Letter
-
Mark
Brief Report: Long-term outcome of a randomized clinical trial comparing methotrexate to cyclophosphamide for remission induction in early systemic antineutrophil cytoplasmic antibody-associated vasculitis
(
- Contribution to journal › Article